376,106 Shares in Roivant Sciences Ltd. $ROIV Purchased by Dorsey Wright & Associates

Dorsey Wright & Associates purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 376,106 shares of the company’s stock, valued at approximately $8,162,000. Roivant Sciences comprises 1.8% of Dorsey Wright & Associates’ holdings, making the stock its 14th biggest holding.

A number of other hedge funds also recently made changes to their positions in the business. TD Asset Management Inc grew its holdings in Roivant Sciences by 94.7% in the 3rd quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after buying an additional 153,800 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Roivant Sciences during the 3rd quarter worth $877,000. HighVista Strategies LLC lifted its holdings in shares of Roivant Sciences by 61.4% during the third quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock worth $1,496,000 after buying an additional 37,590 shares in the last quarter. Neo Ivy Capital Management lifted its holdings in shares of Roivant Sciences by 229.6% during the third quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock worth $3,592,000 after buying an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd lifted its holdings in shares of Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after buying an additional 247,000 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Sanford C. Bernstein began coverage on shares of Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Guggenheim increased their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Trading Up 0.7%

Shares of NASDAQ ROIV opened at $31.43 on Friday. The company has a market cap of $22.61 billion, a price-to-earnings ratio of -52.38 and a beta of 1.13. The stock has a 50-day moving average price of $29.17 and a two-hundred day moving average price of $26.30. Roivant Sciences Ltd. has a 12 month low of $10.70 and a 12 month high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same quarter last year, the business posted ($0.29) earnings per share. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. The trade was a 1.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares in the company, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 703,312 shares of company stock worth $20,805,883 in the last quarter. 10.80% of the stock is owned by insiders.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.